Amicus Therapeutics, Inc. (FOLD) Price Target Analysis
Updated Jun 18, 2026
Analyst Rating: Buy
Based on 24 analysts0.1% Below Target
FOLD trades 0.1% below Wall Street's consensus target of $14.50.
Current Price$14.49
Average Target$14.50
Low$14.50
Median$14.50
High$14.50
Analyst Target Range
Forward P/E40.6x
(Growth Premium)
PEG Ratio—
Implied Growth+513.8%
(High Growth)
Analyst Spread0.0%
(High Agreement)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes FOLD achieves its forward estimates and maintains a stable P/E multiple of 40.6x. This scenario reflects the blended consensus of 24 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
FOLD Price Target Analysis
Updated June 20, 2026As of June 20, 2026, Amicus Therapeutics, Inc. (FOLD) has a Wall Street consensus price target of $14.50, based on estimates from 24 covering analysts. With the stock currently trading at $14.49, this represents a potential upside of +0.1%. The company has a market capitalization of $4.55B.
Analyst price targets range from a low of $14.50 to a high of $14.50, representing a 0% spread in expectations. The median target of $14.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 16 analysts rating the stock as a Buy or Strong Buy,7 rating it Hold, and 1 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, FOLD trades at a trailing P/E of -164.8x and forward P/E of 40.6x. Analysts expect EPS to grow +513.8% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+34.9%
Industry Consensus
Avg Forward P/E
33.2x
(Growth Premium)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 RAREUltragenyx Pharmaceutical Inc. | $2.7B | $27.44 | $48.36 | +76.2% | Buy | — | 33 |
 SRPTSarepta Therapeutics, Inc. | $1.9B | $17.53 | $25.14 | +43.4% | Buy | 5.0x | 54 |
 BMRNBioMarin Pharmaceutical Inc. | $10.5B | $54.69 | $89.93 | +64.4% | Buy | 11.1x | 41 |
 IONSIonis Pharmaceuticals, Inc. | $12.2B | $74.12 | $109.44 | +47.7% | Buy | — | 32 |
 KRYSKrystal Biotech, Inc. | $10.3B | $348.06 | $336.40 | -3.4% | Buy | 44.9x | 17 |
 ACADACADIA Pharmaceuticals Inc. | $3.7B | $21.62 | $33.67 | +55.7% | Buy | 55.6x | 37 |
 PTCTPTC Therapeutics, Inc. | $6.6B | $78.98 | $95.83 | +21.3% | Buy | 89.1x | 26 |
 LGNDLigand Pharmaceuticals Incorporated | $5.5B | $274.88 | $265.33 | -3.5% | Buy | 30.3x | 17 |
 IQVIQVIA Holdings Inc. | $28.5B | $167.77 | $219.44 | +30.8% | Buy | 13.1x | 44 |
 CRLCharles River Laboratories International, Inc. | $8.9B | $185.00 | $214.14 | +15.8% | Buy | 16.7x | 37 |
FOLD — Frequently Asked Questions
Quick answers to the most common questions about buying FOLD stock.
What is the FOLD stock price target for 2026?
The consensus price target for FOLD is $14.5, close to the current price of $14.49 (0.1% implied move). Based on 24 analyst estimates, the stock appears fairly valued near current levels.
Is FOLD a buy, sell, or hold?
FOLD has a consensus rating of "Buy" based on 24 Wall Street analysts. The rating breakdown is predominantly bullish, with 16 Buy/Strong Buy ratings. The consensus 12-month price target of $14.5 implies 0.1% upside from current levels.
Is FOLD stock overvalued or undervalued?
At a forward P/E of 40.6224x, FOLD trades at a premium valuation. The consensus price target of $14.5 (0.1% upside) suggests analysts may view current valuations as stretched.
How high can FOLD stock go?
The most bullish Wall Street analyst has a price target of $14.5 for FOLD, while the most conservative target is $14.5. The consensus of $14.5 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover FOLD stock?
FOLD is well covered by analysts, with 24 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 16 have Buy ratings, 7 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the FOLD stock forecast?
The 12-month FOLD stock forecast based on 24 Wall Street analysts shows a consensus price target of $14.5, with estimates ranging from $14.5 (bear case) to $14.5 (bull case). The median consensus rating is "Buy".
What is FOLD's forward P/E ratio?
FOLD trades at a forward P/E ratio of 40.6x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy FOLD stock?
FOLD appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $14.5 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do FOLD price targets vary so much?
FOLD analyst price targets range from $14.5 to $14.5, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $14.5 consensus represents the middle ground.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare